In 2019, Sanofi Pasteur, the developer of Dengvaxia®, evaluated the specificity and sensitivity of four dengue RDTs (Bio-Rad RDT Dengue IgA/IgG, CTK Biotech OnSite Dengue IgG/IgM, SD BIOLINE Dengue IgM/IgG, and GenBody Dengue IgG/IgM) and observed high specificity overall (>98%) but lower sensitivities (40-70%) (14). This evidence concerns the gene CD40LG and dengue disease.